Roche's soaring sales of Tamiflu bodes well for more good news to come!
Now that flu pandemic has begun, let's review its impact on tamiflu sales since this is the first quarter we can measure the impact of swine flu.
With Roche reporting Q209 results, impact of flu on sales is very clear! Tamifu sales jumped more than 10 folds to US$568M during Q209 compared with a year ago. On a sequential basis, sales jumped 52% with 14% jump in stockpiling and 172% jump in seasonal use.
Of 568M in Q2 09: pandemic stockpile 325M; seasonal use 243M % change vs Q208: US(+710%), Japan(+30977%),Europe(+1423%) In Q109 the corresponding numbers are US(-94%), Japan(+1207%),Europe(+487%)
Although this is only a very small part(~5%) of its revenue, its recently acquired Genentech will provide additional strong earning power and drug pipelines for years to come!